Generics industry complains of EFPIA 'misinformation' on counterfeiting
This article was originally published in Scrip
In a 10 July letter to the European Commission, the European Generic medicines Association (EGA) has drawn attention to what it calls 'misinformation' emanating from the R&D-based industry association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), on counterfeiting in the generics sector.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.